Patents by Inventor Soo Hee Ryu
Soo Hee Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939334Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: GrantFiled: August 10, 2022Date of Patent: March 26, 2024Assignee: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Patent number: 11912710Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: GrantFiled: August 10, 2022Date of Patent: February 27, 2024Assignee: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Publication number: 20240000951Abstract: The present invention relates to a GPX4 protein degradation-inducing compound. Specifically, the present invention provides a bifunctional compound in which a GPX4 protein-binding moiety and a CRBN E3 ubiquitin ligase-binding moiety are linked by a chemical linker, a method for preparing the same, a method for degrading a GPX4 protein using the same, and the use for preventing or treating GPX4-related diseases or ferroptosis-related diseases.Type: ApplicationFiled: December 2, 2021Publication date: January 4, 2024Applicant: UPPTHERAInventors: Soo Hee Ryu, Ji Hoon Ryu, Hwa Jin Lee, Im Suk Min, Han Kyu Lee, Young Jin Choi, Seong Hoon Kim
-
Patent number: 11833208Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: GrantFiled: March 27, 2021Date of Patent: December 5, 2023Assignee: UPPTHERA, INC.Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
-
Publication number: 20230372498Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: ApplicationFiled: August 2, 2023Publication date: November 23, 2023Applicant: UPPTHERAInventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
-
Publication number: 20230242541Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: ApplicationFiled: August 10, 2022Publication date: August 3, 2023Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Publication number: 20230219966Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: ApplicationFiled: August 10, 2022Publication date: July 13, 2023Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Publication number: 20230203006Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: ApplicationFiled: March 27, 2021Publication date: June 29, 2023Applicant: UPPTHERAInventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
-
Publication number: 20230159515Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: ApplicationFiled: March 27, 2021Publication date: May 25, 2023Applicant: UPPTHERAInventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
-
Publication number: 20230158158Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: ApplicationFiled: March 27, 2021Publication date: May 25, 2023Applicant: UPPTHERAInventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
-
Publication number: 20230104076Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: ApplicationFiled: March 27, 2021Publication date: April 6, 2023Inventors: Si Woo CHOI, Soo Hee RYU, Ji Hoon RYU, San Ha SON, Hwa Jin LEE, Seong Hoon KIM, Boas NAM, Im Suk MIN, Hye Guk RYU, Keum Young KANG
-
Publication number: 20230078961Abstract: The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reductase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.Type: ApplicationFiled: March 30, 2021Publication date: March 16, 2023Inventors: Si Woo CHOI, Soo Hee RYU, Ji Hoon RYU, San Ha SON, Hwa Jin LEE, Seong Hoon KIM, Eun Bin LEE, Hye Guk RYU, Im Suk MIN, Jun Kyu LEE
-
Patent number: 11066391Abstract: The present invention relates to bifunctional compounds that induce HMG-CoA reductase degradation, in which in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked. The present invention also relates to a preparation method of the compounds, a method for degrading HMG-CoA reductase using the compounds, and a composition for the prevention or treatment of HMG-CoA reductase-related diseases comprising the compounds.Type: GrantFiled: March 24, 2021Date of Patent: July 20, 2021Assignee: UPPTHERAInventors: Soo Hee Ryu, Hwa Jin Lee, Seong Hoon Kim, Hye Guk Ryu, Eun Bin Lee